Hem › Burkitts lymfom › Texas
Kliniska studier för Burkitts lymfom i Texas
24 studier för Burkitts lymfom söker deltagare vid platser i Texas.
Städer i Texas
- Houston21 studier
- Dallas7 studier
- San Antonio7 studier
- Austin5 studier
- Corpus Christi4 studier
- El Paso4 studier
- Fort Worth4 studier
- Lubbock3 studier
- Killeen3 studier
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- och 10 fler
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Houston Methodist Hospital, Houston
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RekryterarObservationsstudie
Ålder 0 till 38 · Alla kön · Uppdaterad 1 okt. 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- och 7 fler
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
RekryterarFas 3
Ålder 1 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
RekryterarFas 1
Ålder 0 till 18 · Alla kön · Uppdaterad 16 sep. 2026 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- och 10 fler
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- och 12 fler
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
RekryterarFas 2
Ålder 7 till 25 · Alla kön · Uppdaterad 19 aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT06137118Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- MD Anderson Cancer Center, Houston
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- M D Anderson Cancer Center, Houston
RekryterarFas 2
Ålder 15 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RekryterarFas 1/2
Ålder 13 till 90 · Alla kön · Uppdaterad 6 aug. 2026 · NCT06533579Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 15 juli 2026 · NCT01371630Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Houston
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 13 juli 2026 · NCT07109219Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RekryterarFas 2
Ålder 14 och äldre · Alla kön · Uppdaterad 20 maj 2026 · NCT02877303Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 feb. 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 5 nov. 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - St. David's South Austin Medical Center, Austin
- MD Anderson Cancer Center, Houston
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
RekryterarFas 1/2
Ålder 15 till 50 · Alla kön · Uppdaterad 9 sep. 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- The University of Texas M. D. Anderson Cancer Center, Houston
- Methodist Healthcare System, San Antonio
RekryterarFas 2
Ålder 1 till 25 · Alla kön · Uppdaterad 4 maj 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 15 nov. 2024 · NCT06034275Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.